Background: Immunotherapy for cancers is based on the principle that the host's immune system is
Introduction
The incidence of melanoma is increasing at a dramatic rate worldwide. One in 75 Americans will have developed melanoma in the year 2000. 1 Most patients present with early-stage disease that is potentially curable with surgery alone in up to 90% of patients. However, the prognosis for patients with more advanced disease with involvement of regional lymph nodes or distant metastasis is poor, with median survival rates of 24 and 6 months, respectively. In the last few decades, there have been significant advancements in the identification of patients at high risk of developing recur-rences. A number of clinical and histopathologic variables, including thickness and ulceration of primary tumors, the number of lymph node metastasis, and sites of distant metastatic disease, are predictors of survival. 2 Furthermore, lymphatic mapping and sentinel lymph node biopsy techniques have allowed for the identification of patients with regional lymph node metastasis at an even earlier stage of micrometastatic disease. This new surgical procedure combined with a more detailed pathologic examination of the sentinel lymph node provides more accurate staging. 3 Therapeutic intervention in high-risk patients as well as in those with progressive disease could potentially confer long-term benefits.
Current available treatments for patients with melanoma are limited. In patients with metastatic disease, chemotherapy, biologic therapy (eg, interleukin 2 [IL-2], tumor-infiltrating lymphocytes, lymphokine-activated cells) and combination biochemotherapy have yielded low response rates of approximately 20% to 30%. 4, 5 For patients who are at a high risk of developing recurrent disease, treatment with interferon α2b (IFN-α) in the adjuvant setting has been shown to improve disease-free survival (3.8 vs 2.8 years) compared to observation alone in patients with stage IIb or III disease. 6, 7 IFN-α is now an FDA-approved therapy for adjuvant treatment of patients with resected stage III melanoma. However, toxicity to IFN-α is significant, with moderate to severe flu-like symptoms limiting the completion of therapy in nearly 25% of patients. New and innovative approaches and more effective therapies for melanoma are needed. One approach that holds promise is immune therapy.
Historical Perspective
In the 1890s,William Coley first administered a vaccine to treat cancer patients by injecting live bacteria. A review of 30 patients treated with Coley's toxins was published in 1953. 8 The treatment was based on the observation that neoplasms regressed following acute bacterial infection, namely streptococcal infections that produced erysipelas. Examples of complete disappearance without recurrence were documented in patients with extensive, inoperable cancers. However, with the advent of radiation and chemotherapeutic agents, the focus of cancer treatment shifted away from immune activation therapies.
In the 1960s, interest in immunizing against tumors had a rebirth with the observation that irradiated tumor cells in adjuvants such as bacille Calmette-Guérin (BCG), Corynebacterium parvum, and viruses were efficacious in eradicating some tumors. 9, 10 With advances in molecular biology and cellular immunology, much progress has been made in the development of cancer vaccines and immunotherapies. In an effort to enhance immune reactivity, tumor cells have been gene-modified to express various cytokines (interleukins, tumor necrosis factor [TNF], granulocytemacrophage colony-stimulating factor [GM-CSF]), and co-stimulatory molecules (B7.1 and B7.2). The identification of a number of shared melanoma-specific antigens and the peptide fragment epitopes, using molecular cloning techniques, have enabled new approaches targeting tumor cells with greater potency and specificity. These strategies have been tested in clinical trials to treat patients with melanoma. These novel immune therapies in patients have further advanced our knowledge in tumor biology and the interactions with the host immune system.
Vaccines as Cancer Therapy
Cancer vaccines are based on the principle that the immune system of the host is capable of generating immune responses and stimulating defense mechanisms against tumor cells. Although vaccine therapies have been used for centuries to prevent infectious diseases, there are particular challenges in cancer therapy in that the tumor cells have already been exposed to the immune system and have induced a certain degree of tolerance within the host (Figure) . Tumor cells are generally considered to be "poor immunogens." The approaches to vaccine therapy have been either to heighten the immune recognition of tumor cells by
Cancer

Viral infection
Antigen uptake by toleranceinducing APCs making the tumor cells appear more "foreign" to the host immune system or to enhance the host response against tumor cells by increased lymphocytic activation.
In general, the goal of vaccine therapy is to introduce the immunizing "foreign" antigen to antigen-presenting cells (APCs) and to elicit long-lasting immunologic memory from T cells. Antigens may be introduced to APCs by various methods, such as exogenous delivery of antigens (whole cell and protein vaccines), direct transduction (recombinant viral and bacterial vaccines), and direct loading of peptide fragments onto APCs. Active immunization elicits specific or nonspecific reactivity against a tumor antigen by stimulating the patient's own immune system, while passive immunization is the administration of antitumor antibodies or cells against a tumor antigen.
Melanomas are some of the most immunogenic tumors known and are therefore a good model system for immune-based vaccine therapies. Important developments in melanoma vaccines over the years include (1) the understanding of antigen presentation and the role of T-cell activation in generating an antitumor response, (2) the identification of a number of melanoma-specific tumor antigens that are shared by tumors from different patients, and (3) the elucidation of T-cell recognition of specific peptide fragments that are expressed on the surface of tumor cells. Currently, a variety of strategies of tumor immunizations are actively being studied with ongoing clinical trials and are the focus of this article.
Strategies for Targeting Melanoma
Generating an effective immune response requires a complex set of events involving both humoral (antibody) and cell-mediated interactions. Several strategies have been used to enhance the immune response to target melanoma tumor cells. Early on, it was found that nonspecific immune reactivity could be generated by injecting tumor cells with bacteria or viruses. More recent strategies for melanoma vaccine therapies include the use of cytokines and growth factors, whole tumor cells, whole tumor cell vaccines, peptides, antibodies, APCs such as dendritic cells (DCs), DNA, and RNA ( Table 1 ). The identification of melanoma-associated antigens has allowed the strategy of inducing antigen-specific recognition of tumor cells. A number of genetically modified tumor vaccines are aimed at enhancing immunostimulatory mechanisms within the host, including tumor antigen(s) recognition, increased cytokine release, activation of APCs, and the use of costimulation to recruit activated immune reactive cells.
Whole Tumor Cell Vaccines
Whole tumor vaccines have the advantage of immunizing the patient with diverse antigens that are present on the tumor surface without knowing the exact antigen(s) that may be responsible for tumor rejection, ie, whole tumor cells are used as the source of antigen(s). Autologous tumor cells are derived from tumors surgically resected from patients who will be vaccinated with their own manipulated tumor cells. These tumor cells are irradiated or attenuated in some fashion to prevent proliferation in vivo and reinjected into patients with or without immunomodulators such as BCG or C. parvum. 9, 10 However, a limitation to autologous tumor vaccines is that a tumor specimen must be obtained from each patient. To circumvent this problem, allogeneic tumor cell vaccines can be generated using established stable cultured cell lines derived from tumors previously obtained from patients. The rationale for the efficacy of allogeneic tumor cell vaccines is that there are melanoma-specific antigens that are shared by different patients. 11 These shared antigens are immunogenic and can enhance the host's immune system to generate an effective antitumor response. Allogeneic vaccines also have the advantage of being more readily applicable to a greater number of patients regardless of the availability of bulky tumor.
A major disadvantage of whole-cell tumor vaccines is that tumor cells, as such, are generally not immunogenic. These tumor cells have already demonstrated their tumorigenic and metastatic potential by escaping the host immune system. Other approaches such as the use of purified fractions of allogeneic tumor cell lines as antigens that are shed by the tumor cells into the culture media have been used to improve immunogenicity. 12 Heat shock protein extracts purified from autologous tumor cells have also been shown to have antitumor reactivity against the tumor cells from which they were derived. 13 Mitchell et al 14 reported their experience using allogeneic tumor vaccines. In a series of studies, 106 patients were treated with Detox vaccine for metastatic disease. Twenty patients had an objective clinical response, 5 with a complete response. This led to the current ongoing phase III randomized trials of vaccine 16 demonstrated a 34% and 23% 5-year survival rate in patients with stage III and IV disease, respectively, who had been rendered disease-free before treatment. The CancerVax vaccine is currently being tested in an NCI-funded multicenter national trial. However, a large phase III randomized trial comparing vaccinia melanoma oncolysate (derived from allogeneic melanoma cells) vs placebo in patients with resected nodal metastasis showed no survival benefit in the vaccinated patient. 17 Thus, preliminary data from singlearm studies suggest a possible benefit of whole-cell vaccines, but randomized data have not yet confirmed a therapeutic benefit for this approach. There are numerous potential approaches to optimizing immunogenicity of whole-cell vaccines. Thus, the failure of one approach in a randomized, prospective trial cannot be interpreted as failure of this approach generally. However, there is enthusiasm for evaluating other approaches, in which immune responses to the vaccines may be more readily evaluated.
Synthetic Vaccines Targeting Antibody Responses
An alternative approach is to vaccinate with defined tumor antigens that are created synthetically. Several cell-surface molecules on melanoma cells may be targeted by antibodies, and antibodies to some of these molecules are induced in patients with melanoma. 18 A substantial series of clinical studies has been performed with vaccines intended to induce protective antibody responses to the melanoma antigen, GM2, a cell-surface ganglioside. In a pilot study, Livingston and colleagues 19 showed a trend toward improved survival for patients with stage III disease who received GM2 ganglioside/BCG and low-dose chemotherapy, and they demonstrated that patients developed antibodies to the GM2 ganglioside. This has led to a larger randomized phase III ECOG study comparing GM2/KLH in adjuvant QS-21 vaccine to highdose IFN-α. This study was recently closed due to an early significant survival benefit associated with adjuvant IFN α-2b. 20 
Peptide Vaccines
Evidence demonstrating the presence of shared antigens on melanoma tumor cells of different patients led to the cloning and identification of several melanoma-associated antigens. 11 Furthermore, it is now known that the antigenic epitopes responsible for eliciting an antitumor response consist of small peptide fragments. These peptides are endogenously processed by the tumor cell or an APC and presented to the T cell in association with a major histocompatibility complex (MHC) molecule. The mechanism of peptide vaccination requires the loading of peptide fragments onto empty MHC class I or II molecules. The peptide is generally administered in conjunction with a delivery system such as incomplete Freund's adjuvant. A number of shared melanoma-associated antigens and their DNA sequences are now known. The majority of peptides have been found to be presented on MHC class I molecules ( Table 2 ).
The antigenic peptides can be produced synthetically from purified amino acids, therefore obviating the need to obtain tissue from patients, as in the case for whole tumor cell vaccines. In addition, the patients can be monitored to detect specific immune reactivity after immunizations. The disadvantage is that because the vaccine consists of one specific antigen or a peptide fragment, it is possible that the tumors will undergo mutations and escape the immune system or that more than one particular tumor antigen may be required to generate a clinically effective antitumor response. It is possible that an effective tumor vaccine may require immunization with multiple antigens. Another disadvantage of the peptide-based vaccine is the need for patient selection based on HLA type, since peptides may bind only to a certain MHC class I motif. Defined peptide epitopes are not necessarily expressed on the surface of tumor cells, and posttranslational modifications may affect the recognition of tumor associated peptides. There is increasing consensus that effective peptide vaccines will incorporate multiple different peptides in order to increase the breadth of the immune response generated. Also, MHC class I-restricted peptides do not engage CD4+ lymphocytes, which have a critical role in the induction of an effective immune response. Thus, there is a rationale for vaccinating with combinations of peptides restricted by MHC class I and MHC class II to permit induction of both CD8+ and CD4+ responses to tumor antigens.
Clinical trials using peptide vaccination approaches with epitopes MAGE-1, MAGE-3, MART-1, gp100, tyrosinase, and gp75 have been used for immunization. A phase I trial with MAGE-3 peptide vaccination in incomplete Freund's adjuvant showed promising results in patients with advanced melanoma. 69 Investigators at the NCI demonstrated that a gp100 peptide modified at a single amino acid residue administered with high-dose IL-2 significantly enhanced immuno- 
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genicity compared to wild-type gp100. In phase I clinical trials, patients treated with the modified gp100 vaccine had responses with clinical tumor regression. A multi-institutional clinical trial randomizing patients with melanoma to modified gp100 vaccine plus highdose IL-2 vs IL-2 alone was recently opened for patient accrual. 70 Cytokine and Growth Factor Modulation
Cytokines are soluble proteins that are important in the regulatory function of the cells of the immune system. The number of cytokines identified continues to expand, but the cytokines that have been used clinically to treat patients with cancer include IL-2, interferons (IFN-α, IFN-β, IFN-γ) , GM-CSF, and TNF. Intravenous administration of recombinant IL-2 has been used in clinical trials for patients with metastatic melanoma with overall response rates of approximately 20%. 4, 71 In a study by Leong et al, 72 rhGM-CSF in addition to autologous tumor vaccine was used to treat patients with metastatic melanoma with response rates of 20% and a 10% CR rate.
Genetically modified cell-based vaccines encoding for cytokines and co-stimulatory molecules allow sustained local release of cytokines to enhance a potent local inflammatory response without generating systemic side effects. GM-CSF appears to be a strong promoter of local DCs at the vaccination site. 73 Antigen-Presenting Cells/Dendritic Cells DCs are professional APCs that are critical in the initiation of cellular responses in naive T lymphocytes. They take up antigen, circulate and migrate to secondary lymphoid organs, and stimulate resting T cells in an MHC class I and class II restricted manner. The majority of the studies showing efficacy of DCs in cancer therapy have been in preclinical mouse models. Antigenic peptides have been directly loaded onto DCs to induce specific antitumor response. In these animal models, peptide-pulsed DC vaccines appear to be a more efficient method of inducing an antitumor response than peptide alone. 74, 75 New methods in isolating DCs in humans from peripheral blood in larger quantities have allowed the use of DCs as a therapeutic modality. Clinical vaccination trials using DCs have shown promise as a potent antitumor therapy. A study reported by Nestle et al 76 using autologous DCs were pulsed with autologous tumor lysates or peptides showed efficacy. Sixteen patients with metastatic melanoma were immunized, and objective responses were seen in 5 of the 16 patients (2 CRs and 3 PRs). Delayed hypersensitivity reaction to peptide-pulsed DCs and peptide-specific CTLs were demonstrated. In another trial, 77 16 patients with metastatic melanoma were treated with DCs pulsed with tyrosinase 368-376 (370D) and gp100 [209] [210] [211] [212] [213] [214] [215] [216] [217] (210M) peptides restricted by HLA class I A*0201. One patient had a CR of lung and pleural disease after 2 cycles of DC therapy. Two additional patients had stable disease, and 2 patients had mixed responses. Five of 16 patients had an immune response to gp100 or tyrosinase as demonstrated by INF-γ enzyme-linked immunosorbent assay (ELISA). Four of 5 were clinically stable or had tumor regression. 77 The optimal strategy of using DCs in vaccination is critically important for the success of immunization. It has been reported that nonactivated, relatively immature DCs were not effective in patients with melanoma. 78 However, SchulerThurner and collegues 79 recently reported that 3-5 biweekly vaccinations of DCs pulsed with MAGE-3A2.1 tumor and the recall Ag-tetanus toxoid generated Agspecific effector CD8+ T cells in all 8 patients treated for metastatic melanoma. Future studies are needed to address the issues such as optimal dosage, route of administration, and antigens presented.
DNA and RNA Vaccines
Injection of nucleic acids has been shown to induce activation of APCs which then are responsible for presenting the antigens to T cells. 80 One advantage of DNA and RNA vaccines is that they deliver genetic material without the difficulties associated with the development of immune reactivity against viral vectors. Approaches to DNA vaccines to date have used DNA encoding for cytokines, co-stimulatory molecules (eg, B7-1), or melanoma-associated antigens. In animal models, DNA expressing melanoma-specific antigen gp100/pmel17 was used to effectively immunize mice and reduce tumor formation by 50%. 81 Investigators from Duke University treated patients with central nervous system tumors and metastatic malignancies using tumor RNA pulsed or transfected into DCs to induce antitumor activity.
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Conclusions
There is a major collaborative effort in the United States and Europe involving the NCI, pharmaceutical companies, hospitals, and institutes for research and development of cancer vaccines. More than 95 tumor vaccines are in development, many of which are for the treatment of melanoma patients. A variety of approaches can be used to enhance immune reactivity against tumor cells. In November 2000, the first therapeutic melanoma vaccine, Melacine, became available for commercial sale in Canada. Melacine vaccine consists of two lysed melanoma tumor cell lines in combination with an adjuvant, lipid A, and mycobacterial cell wall skeleton. In the United States, the vaccine is still in phase III clinical trials. 84 The future of cancer vaccines is exciting and promising. However, many unanswered questions and challenges lie ahead. Optimization of strategies, route, timing, and dose of administration will be critical in the development of melanoma vaccines. Continued efforts, clinical trials, and scientific progress will allow the development of more potent targeted therapies for melanoma patients.
